About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Hypertension with Metabolic Alkalosis and Hypokalaemia - Could it be Aldosterone?
James Cheng Jiang1, Ronald Castelino2,3, Surjit Tarafdar1,4,5
1Acute Medical Unit and Departments of 3Pharmacy and 4Renal Medicine, Blacktown Hospital, NSW 2148, Australia; 2Faculty of Medicine and Health, University of Sydney, NSW 2148, Australia; 5School of Medicine, Western Sydney University, Sydney, Australia.
Corresponding Author:
Dr. Surjit Tarafdar
Email: surjit.tarafdar@health.nsw.gov.au
Received: 14-JAN-2019 Accepted: 03-MAR-2019 Published Online: 20-MAR-2019
DOI: http://dx.doi.org/10.17659/01.2019.0015
Abstract
Background: Hypertension has a worldwide prevalence of 31% and contributes markedly to death from stroke and coronary heart disease. Up to 10% of hypertensive patients have secondary hypertension; an even higher prevalence is present amongst patients below the age of 30. The two commonest causes of secondary hypertension, primary aldosteronism and renovascular disease, may both present with metabolic alkalosis and/or hypokalaemia. While both conditions are associated with raised plasma aldosterone, plasma renin concentration is low in primary aldosteronism and high in renovascular hypertension, giving rise to the characteristically high plasma aldosterone concentration: plasma renin concentration (>30:1) in the former. Case Report: We hereby report two hypertensive cases who presented with metabolic alkalosis and/or hypokalaemia. The two common causes of secondary hypertension, namely primary aldosteronism (PA) and renovascular disease, are presented in this case series. Conclusion: Diagnosis of secondary cause of hypertension such as primary aldosteronism or renovascular disease leads to targeted anti-hypertensive therapy resulting in better patient management.
Keywords : Aldosterone, Alkalosis, Antihypertensive Agents, Hypertension, Hypokalaemia, Renin.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Dec 04, 2024